Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 9 of 9 entries
Sorted by: Best Match Show Resources per page
Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine.

Genes & diseases

Qin JJ, Li X, Hunt C, Wang W, Wang H, Zhang R.
PMID: 30320185
Genes Dis. 2018 Jul 20;5(3):204-219. doi: 10.1016/j.gendis.2018.07.002. eCollection 2018 Sep.

The p53 tumor suppressor plays a major role in controlling the initiation and development of cancer by regulating cell cycle arrest, apoptosis, senescence, and DNA repair. The MDM2 oncogene is a major negative regulator of p53 that inhibits the...

Cite
Qin JJ, Li X, Hunt C, et al. Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine. Genes Dis. 2018;5(3):204-219doi: 10.1016/j.gendis.2018.07.002.
Qin, J. J., Li, X., Hunt, C., Wang, W., Wang, H., & Zhang, R. (2018). Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine. Genes & diseases, 5(3), 204-219. https://doi.org/10.1016/j.gendis.2018.07.002
Qin, Jiang-Jiang, et al. "Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine." Genes & diseases vol. 5,3 (2018): 204-219. doi: https://doi.org/10.1016/j.gendis.2018.07.002
Qin JJ, Li X, Hunt C, Wang W, Wang H, Zhang R. Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine. Genes Dis. 2018 Jul 20;5(3):204-219. doi: 10.1016/j.gendis.2018.07.002. eCollection 2018 Sep. PMID: 30320185; PMCID: PMC6176154.
Copy Download .nbib Format: NLM
Inhibiting β-Catenin by β-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy.

Frontiers in pharmacology

Qin JJ, Wang W, Li X, Deokar H, Buolamwini JK, Zhang R.
PMID: 29387014
Front Pharmacol. 2018 Jan 17;9:5. doi: 10.3389/fphar.2018.00005. eCollection 2018.

The β-catenin and MDM2 oncoproteins are overexpressed and constitutively activated in human pancreatic cancer and contribute to its initiation, progression, and metastasis. The Wnt/β-catenin signaling pathway strongly interacts with the MDM2-p53 signaling pathway, accelerating the tumorigenesis and its development....

Cite
Qin JJ, Wang W, Li X, et al. Inhibiting β-Catenin by β-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy. Front Pharmacol. 2018;9:5doi: 10.3389/fphar.2018.00005.
Qin, J. J., Wang, W., Li, X., Deokar, H., Buolamwini, J. K., & Zhang, R. (2018). Inhibiting β-Catenin by β-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy. Frontiers in pharmacology, 95. https://doi.org/10.3389/fphar.2018.00005
Qin, Jiang-Jiang, et al. "Inhibiting β-Catenin by β-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy." Frontiers in pharmacology vol. 9 (2018): 5. doi: https://doi.org/10.3389/fphar.2018.00005
Qin JJ, Wang W, Li X, Deokar H, Buolamwini JK, Zhang R. Inhibiting β-Catenin by β-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy. Front Pharmacol. 2018 Jan 17;9:5. doi: 10.3389/fphar.2018.00005. eCollection 2018. PMID: 29387014; PMCID: PMC5776119.
Copy Download .nbib Format: NLM
Dihydroartemisinin selectively inhibits PDGFRα-positive ovarian cancer growth and metastasis through inducing degradation of PDGFRα protein.

Cell discovery

Li X, Ba Q, Liu Y, Yue Q, Chen P, Li J, Zhang H, Ying H, Ding Q, Song H, Liu H, Zhang R, Wang H.
PMID: 29387451
Cell Discov. 2017 Nov 21;3:17042. doi: 10.1038/celldisc.2017.42. eCollection 2017.

To develop traditional medicines as modern pharmacotherapies, understanding their molecular mechanisms of action can be very helpful. We have recently reported that Artemisinin and its derivatives, which are clinically used anti-malarial drugs, have significant effects against ovarian cancer, but...

Cite
Li X, Ba Q, Liu Y, et al. Dihydroartemisinin selectively inhibits PDGFRα-positive ovarian cancer growth and metastasis through inducing degradation of PDGFRα protein. Cell Discov. 2017;3:17042doi: 10.1038/celldisc.2017.42.
Li, X., Ba, Q., Liu, Y., Yue, Q., Chen, P., Li, J., Zhang, H., Ying, H., Ding, Q., Song, H., Liu, H., Zhang, R., & Wang, H. (2017). Dihydroartemisinin selectively inhibits PDGFRα-positive ovarian cancer growth and metastasis through inducing degradation of PDGFRα protein. Cell discovery, 317042. https://doi.org/10.1038/celldisc.2017.42
Li, Xiaoguang, et al. "Dihydroartemisinin selectively inhibits PDGFRα-positive ovarian cancer growth and metastasis through inducing degradation of PDGFRα protein." Cell discovery vol. 3 (2017): 17042. doi: https://doi.org/10.1038/celldisc.2017.42
Li X, Ba Q, Liu Y, Yue Q, Chen P, Li J, Zhang H, Ying H, Ding Q, Song H, Liu H, Zhang R, Wang H. Dihydroartemisinin selectively inhibits PDGFRα-positive ovarian cancer growth and metastasis through inducing degradation of PDGFRα protein. Cell Discov. 2017 Nov 21;3:17042. doi: 10.1038/celldisc.2017.42. eCollection 2017. PMID: 29387451; PMCID: PMC5787695.
Copy Download .nbib Format: NLM
A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance.

Genes & diseases

Wang W, Hu B, Qin JJ, Cheng JW, Li X, Rajaei M, Fan J, Yang XR, Zhang R.
PMID: 31832522
Genes Dis. 2019 Jun 19;6(4):419-430. doi: 10.1016/j.gendis.2019.06.001. eCollection 2019 Dec.

Overexpression of the

Cite
Wang W, Hu B, Qin JJ, et al. A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance. Genes Dis. 2019;6(4):419-430doi: 10.1016/j.gendis.2019.06.001.
Wang, W., Hu, B., Qin, J. J., Cheng, J. W., Li, X., Rajaei, M., Fan, J., Yang, X. R., & Zhang, R. (2019). A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance. Genes & diseases, 6(4), 419-430. https://doi.org/10.1016/j.gendis.2019.06.001
Wang, Wei, et al. "A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance." Genes & diseases vol. 6,4 (2019): 419-430. doi: https://doi.org/10.1016/j.gendis.2019.06.001
Wang W, Hu B, Qin JJ, Cheng JW, Li X, Rajaei M, Fan J, Yang XR, Zhang R. A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance. Genes Dis. 2019 Jun 19;6(4):419-430. doi: 10.1016/j.gendis.2019.06.001. eCollection 2019 Dec. PMID: 31832522; PMCID: PMC6889017.
Copy Download .nbib Format: NLM
JWA regulates TRAIL-induced apoptosis via MARCH8-mediated DR4 ubiquitination in cisplatin-resistant gastric cancer cells.

Oncogenesis

Wang Q, Chen Q, Zhu L, Chen M, Xu W, Panday S, Wang Z, Li A, Røe OD, Chen R, Wang S, Zhang R, Zhou J.
PMID: 28671676
Oncogenesis. 2017 Jul 03;6(7):e353. doi: 10.1038/oncsis.2017.57.

Platinum chemotherapeutics are widely used to treat solid malignant tumors, including gastric cancer (GC). Drug resistance to platinum compounds may result in cancer relapse and decreased survival. The identification and development of novel agents to reactivate apoptosis pathways in...

Cite
Wang Q, Chen Q, Zhu L, et al. JWA regulates TRAIL-induced apoptosis via MARCH8-mediated DR4 ubiquitination in cisplatin-resistant gastric cancer cells. Oncogenesis. 2017;6(7):e353doi: 10.1038/oncsis.2017.57.
Wang, Q., Chen, Q., Zhu, L., Chen, M., Xu, W., Panday, S., Wang, Z., Li, A., Røe, O. D., Chen, R., Wang, S., Zhang, R., & Zhou, J. (2017). JWA regulates TRAIL-induced apoptosis via MARCH8-mediated DR4 ubiquitination in cisplatin-resistant gastric cancer cells. Oncogenesis, 6(7), e353. https://doi.org/10.1038/oncsis.2017.57
Wang, Q, et al. "JWA regulates TRAIL-induced apoptosis via MARCH8-mediated DR4 ubiquitination in cisplatin-resistant gastric cancer cells." Oncogenesis vol. 6,7 (2017): e353. doi: https://doi.org/10.1038/oncsis.2017.57
Wang Q, Chen Q, Zhu L, Chen M, Xu W, Panday S, Wang Z, Li A, Røe OD, Chen R, Wang S, Zhang R, Zhou J. JWA regulates TRAIL-induced apoptosis via MARCH8-mediated DR4 ubiquitination in cisplatin-resistant gastric cancer cells. Oncogenesis. 2017 Jul 03;6(7):e353. doi: 10.1038/oncsis.2017.57. PMID: 28671676; PMCID: PMC5541709.
Copy Download .nbib Format: NLM
Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and Androgen.

Frontiers in pharmacology

Qin JJ, Li X, Wang W, Zi X, Zhang R.
PMID: 29311926
Front Pharmacol. 2017 Dec 14;8:917. doi: 10.3389/fphar.2017.00917. eCollection 2017.

The MDM2 and MDMX oncogenes are overexpressed in various types of human cancer and are highly associated with the initiation, progression, metastasis and chemotherapeutic resistance of these diseases, including prostate cancer. The present study was designed to test a...

Cite
Qin JJ, Li X, Wang W, et al. Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and Androgen. Front Pharmacol. 2017;8:917doi: 10.3389/fphar.2017.00917.
Qin, J. J., Li, X., Wang, W., Zi, X., & Zhang, R. (2017). Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and Androgen. Frontiers in pharmacology, 8917. https://doi.org/10.3389/fphar.2017.00917
Qin, Jiang-Jiang, et al. "Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and Androgen." Frontiers in pharmacology vol. 8 (2017): 917. doi: https://doi.org/10.3389/fphar.2017.00917
Qin JJ, Li X, Wang W, Zi X, Zhang R. Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and Androgen. Front Pharmacol. 2017 Dec 14;8:917. doi: 10.3389/fphar.2017.00917. eCollection 2017. PMID: 29311926; PMCID: PMC5735069.
Copy Download .nbib Format: NLM
Synthesis, Biological Evaluation and Modeling Studies of New Pyrido[3,4-.

Drug designing : open access

Patil SA, Addo JK, Deokar H, Sun S, Wang J, Li W, Suttle DP, Wang W, Zhang R, Buolamwini JK.
PMID: 29354330
Drug Des. 2017 Mar;6(1). doi: 10.4172/2169-0138.1000143. Epub 2017 Mar 01.

OBJECTIVE: There is an urgent need drugs against particularly difficult to treat solid tumors such as pancreatic, triple negative breast, lung, colon, metastatic prostate cancers and melanoma. Thus, the objective of this study was to synthesize compounds based computational...

Cite
Patil SA, Addo JK, Deokar H, et al. Synthesis, Biological Evaluation and Modeling Studies of New Pyrido[3,4-. Drug Des. 2017;6(1)doi: 10.4172/2169-0138.1000143.
Patil, S. A., Addo, J. K., Deokar, H., Sun, S., Wang, J., Li, W., Suttle, D. P., Wang, W., Zhang, R., & Buolamwini, J. K. (2017). Synthesis, Biological Evaluation and Modeling Studies of New Pyrido[3,4-. Drug designing : open access, 6(1), . https://doi.org/10.4172/2169-0138.1000143
Patil, Shivaputra A, et al. "Synthesis, Biological Evaluation and Modeling Studies of New Pyrido[3,4-." Drug designing : open access vol. 6,1 (2017). doi: https://doi.org/10.4172/2169-0138.1000143
Patil SA, Addo JK, Deokar H, Sun S, Wang J, Li W, Suttle DP, Wang W, Zhang R, Buolamwini JK. Synthesis, Biological Evaluation and Modeling Studies of New Pyrido[3,4-. Drug Des. 2017 Mar;6(1). doi: 10.4172/2169-0138.1000143. Epub 2017 Mar 01. PMID: 29354330; PMCID: PMC5771418.
Copy Download .nbib Format: NLM
Identification of lineariifolianoid A as a novel dual NFAT1 and MDM2 inhibitor for human cancer therapy.

Journal of biomedical research

Qin JJ, Sarkar S, Voruganti S, Agarwal R, Wang W, Zhang R.
PMID: 27533941
J Biomed Res. 2016 Jul;30(4):322-33. doi: 10.7555/JBR.30.20160018. Epub 2016 May 25.

There is an increasing interest in development of novel anticancer agents that target oncogenes. We have recently discovered that nuclear factor of activated T cells 1 (NFAT1) is a novel regulator of the Mouse Double Minute 2 (MDM2) oncogene...

Cite
Qin JJ, Sarkar S, Voruganti S, et al. Identification of lineariifolianoid A as a novel dual NFAT1 and MDM2 inhibitor for human cancer therapy. J Biomed Res. 2016;30(4):322-33doi: 10.7555/JBR.30.20160018.
Qin, J. J., Sarkar, S., Voruganti, S., Agarwal, R., Wang, W., & Zhang, R. (2016). Identification of lineariifolianoid A as a novel dual NFAT1 and MDM2 inhibitor for human cancer therapy. Journal of biomedical research, 30(4), 322-33. https://doi.org/10.7555/JBR.30.20160018
Qin, Jiang-Jiang, et al. "Identification of lineariifolianoid A as a novel dual NFAT1 and MDM2 inhibitor for human cancer therapy." Journal of biomedical research vol. 30,4 (2016): 322-33. doi: https://doi.org/10.7555/JBR.30.20160018
Qin JJ, Sarkar S, Voruganti S, Agarwal R, Wang W, Zhang R. Identification of lineariifolianoid A as a novel dual NFAT1 and MDM2 inhibitor for human cancer therapy. J Biomed Res. 2016 Jul;30(4):322-33. doi: 10.7555/JBR.30.20160018. Epub 2016 May 25. PMID: 27533941; PMCID: PMC4946323.
Copy Download .nbib Format: NLM
QSAR Studies of New Pyrido[3,4-.

Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents

Deokar H, Deokar M, Wang W, Zhang R, Buolamwini JK.
PMID: 31360052
Med Chem Res. 2018 Dec;27(11):2466-2481. doi: 10.1007/s00044-018-2250-5. Epub 2018 Oct 03.

We have discovered a new class of pyrido[

Cite
Deokar H, Deokar M, Wang W, et al. QSAR Studies of New Pyrido[3,4-. Med Chem Res. 2018;27(11):2466-2481doi: 10.1007/s00044-018-2250-5.
Deokar, H., Deokar, M., Wang, W., Zhang, R., & Buolamwini, J. K. (2018). QSAR Studies of New Pyrido[3,4-. Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, 27(11), 2466-2481. https://doi.org/10.1007/s00044-018-2250-5
Deokar, Hemantkumar, et al. "QSAR Studies of New Pyrido[3,4-." Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents vol. 27,11 (2018): 2466-2481. doi: https://doi.org/10.1007/s00044-018-2250-5
Deokar H, Deokar M, Wang W, Zhang R, Buolamwini JK. QSAR Studies of New Pyrido[3,4-. Med Chem Res. 2018 Dec;27(11):2466-2481. doi: 10.1007/s00044-018-2250-5. Epub 2018 Oct 03. PMID: 31360052; PMCID: PMC6662939.
Copy Download .nbib Format: NLM
Showing 1 to 9 of 9 entries